Brain Computer Interface (BCI) Enables Thought-Controlled Walking after Spinal Cord Injury
Pioneering study in Nature demonstrates that adding a BCI to ONWARD® ARC Therapy™ can enable thought-controlled standing, walking, and stair climbing
EINDHOVEN, the Netherlands, May 24, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces a publication in Natureshowing that a wireless brain-computer interface (BCI) can use thought to modulate ARC Therapy. Researchers reported that when paired with ARC Therapy, an implanted BCI allowed an individual to gain augmented control over when and how he moved his paralyzed legs.
“This publication shows the remarkable potential of ARC Therapy to be enhanced with the introduction of a BCI, facilitating more natural movement based on the thoughts of a person living with paralysis,” said Dave Marver, CEO of ONWARD. “We have positioned ONWARD as a leader in the BCI field with our unique understanding of spinal cord stimulation for people with SCI.”
“The BCI establishes a continuous link between movement intentions and spinal cord stimulation, allowing for more natural restoration of mobility,” said neuroscientist Grégoire Courtine, professor at EPFL, and co-author of the Nature paper. “I look forward to working with the ONWARD team to advance this important new technology.”
The data published today are part of an ongoing clinical feasibility study investigating the safety and preliminary effectiveness of brain-controlled spinal cord stimulation after SCI. The study is being coordinated by .NeuroRestore co-Directors – Grégoire Courtine and Jocelyne Bloch, a neurosurgeon at Lausanne University Hospital (CHUV) – as well as Guillaume Charvet, Head of the Medical Device Development Lab at CEA-Leti / Clinatec.
All ONWARD devices and therapies, including but not limited to ARC-IM, ARC-EX, and ARC Therapy, are investigational and not available for commercial use.
About ONWARD Medical
ONWARD is a medical technology company creating therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and movement disabilities. Building on more than a decade of science and preclinical research conducted at leading neuroscience laboratories, the Company has received nine Breakthrough Device Designations from the U.S. Food and Drug Administration for its ARC Therapy™ platform.
ONWARD® ARC Therapy, which can be delivered by external ARC-EX™ or implantable ARC-IM™ systems, is designed to deliver targeted, programmed spinal cord stimulation. Positive results were presented in 2023 from the Company’s pivotal study, called Up-LIFT, evaluating the ability for transcutaneous ARC Therapy to improve upper extremity strength and function. The Company is now preparing regulatory approval submissions for ARC-EX for the US and Europe. In parallel, the Company is conducting studies with its implantable ARC-IM platform, which demonstrated positive interim clinical outcomes for improved blood pressure regulation following SCI in 2022. These studies include combination use of ARC-IM with a brain-computer interface (BCI).
Headquartered in Eindhoven, the Netherlands, ONWARD has a Science and Engineering Center in Lausanne, Switzerland and a U.S. office in Boston, Massachusetts. The Company also has an academic partnership with .NeuroRestore, a collaboration between EPFL, the Swiss Federal Institute of Technology in Lausanne, and Lausanne University Hospital (CHUV).
For more information, visit ONWD.com, and connect with us on LinkedIn and YouTube.
For Media Enquiries:
Aditi Roy, VP Communications
For Investor Enquiries:
Lara Smith Weber, CFO
Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. All ONWARD devices and therapies referenced here, including but not limited to ARC-IM, ARC-EX, and ARC Therapy, are investigational and not available for commercial use.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Telesis Bio Announces Closing of $28.0 Million Private Placement of Preferred Stock And Warrants to Purchase an Additional $46.2 Million of Common Stock5.6.2023 23:30:00 CEST | Press release
SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in molecular biology automation solutions for multi-omic and synthetic biology applications, today announced the closing of its private placement of redeemable convertible preferred stock and warrants resulting in initial gross proceeds of $28.0 million to Telesis Bio. The warrants issued in the private placement will provide Telesis Bio with approximately $46.2 million in additional gross proceeds if they are cash exercised. The financing was led by Novalis LifeSciences LLC with participation from Northpond Ventures, BroadOak Capital Partners and M-185 Corporation, an affiliate of the Company’s Chief Executive Officer and Founder, Todd R. Nelson, PhD. The Company also announced the appointment of Paul Meister, a partner at Novalis LifeSciences LLC, to the Company’s board of directors immediately following the closing. Please refer to the Company’s Form 8-K to be filed with the Securities and Exchang
Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress5.6.2023 22:01:00 CEST | Press release
All 7 out of 7 eligible patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter’s Transformation (RT), responded to treatment (Objective Response Rate of 100%)1 GLPG5201 showed no cytokine release syndrome (CRS) higher than grade 2, or immune effector cell-associated neurotoxicity syndrome (ICANS)2 A functionally closed, automated manufacturing platform for cell therapies at the point-of-care will be shown at the Galapagos booth A.103at the EHA 2023 congress Mechelen, Belgium; 5 June 2023,22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will feature theCAR-T point-of-care manufacturing platform and willpresent previously disclosed initial Phase 1/2 data with CD19 CAR-T candidate, GLPG5201, at the European Hematology Association (EHA) 2023 congress, taking place from 8 June to 11June 2023 in Frankfurt, Germany. “Patients who develop rrCLL and become resistant to new agents have a very poor prognosis and a significant high
Hoylu AB: Publicerar årsredovisning för 20225.6.2023 21:15:00 CEST | Pressemelding
Hoylu AB (publ) meddelar idag att årsredovisningen för räkenskapsåret 2022 bifogas detta pressmeddelande och finns tillgänglig på bolagets hemsida: (https://www.hoylu.com/investor-relations/financial-reports/). För mer information kontakta: Truls Baklid, CEO, +47 924 38 900 Email: email@example.com Karl Wiersholm, CFO, +1 425 829 2316 Email: firstname.lastname@example.org Om Hoylu Hoylus uppdrag är att ge distribuerade team möjlighet att samarbeta enkelt och sömlöst samtidigt som de alltid håller sig synkroniserade. Hoylus Adaptive Workspaces™ hjälper företag såväl stora som små att driva projekt, program och initiativ över olika tidszoner och kontinenter med samma engagemang och tydlighet som om alla arbetade i samma rum. För mer information: www.hoylu.com Kortnamn: Hoylu Marknadsplats: Nasdaq First North Growth Stockholm Certified Adviser: Mangold Fondkommission AB +46 (0) 8 50 301 550; email@example.com Publicering Informationen lämnades, genom ovanstående kontaktpersons försorg för offentliggörande den 5 ju
Hoylu AB: Publishes its Annual Report for 20225.6.2023 21:15:00 CEST | Press release
Hoylu AB (publ) announced today that the Annual Report for 2022 is attached to this press release and is available on Hoylu's web site: (https://www.hoylu.com/investor-relations/financial-reports/). For more information contact: Truls Baklid, CEO, +47 924 38 900 Email: firstname.lastname@example.org Karl Wiersholm, CFO, +1 425 829 2316 Email: email@example.com About Hoylu Hoylu’s visual collaboration technology empowers distributed teams to translate ideas into actions. Large enterprises as well as small and medium companies rely on Hoylu to run projects, programs, and initiatives across time zones and continents as seamlessly as when working in the same room. For more information: www.hoylu.com Try Hoylu for free: https://app.hoylu.com/ Ticker symbol: Hoylu Marketplace: Nasdaq First North Growth Market Certified Adviser: Mangold Fondkommission AB +46 (0) 8 50 301 550, firstname.lastname@example.org Publication The information was submitted for publication, through the agency of the contact person set out above, at 21:15 CE
Nokia Corporation: Repurchase of own shares on 05.06.20235.6.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 5 June 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 05.06.2023 Espoo, Finland – On 5 June 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL308,5933.85CEUX48,4053.86AQEU4,7293.86TQEX3,3733.87Total365,1003.86 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023 and en